ORAL THERAPEUTICS AND PHARMACOLOGY
Online ISSN : 1884-4928
Print ISSN : 0288-1012
ISSN-L : 0288-1012
Clinical application of Granisetron for oral cancer
MASAYUKI MORIKAWAKATSUMI NISHIJIMASHIN TAKAGISHIGEKI KOYAMAMASAHIRO IWATA
Author information
JOURNAL FREE ACCESS

1993 Volume 12 Issue 3 Pages 175-180

Details
Abstract
Recently, the number of deaths by malignant tumor has been rising. In oral surgery, many types of malignant tumors, particularly squamous cell carcinoma, have been found. Firstly malignant tumor is difficult to treat, thus we have determined to reduce the tumor size. Therefore, we have infused an anti-cancer drug at a high dose even if the therapy against some side effects is incomplete.
Cisplatin is popular as an anticancer drug with some side effects, such as nausea, vomiting, and bone marrow suppression. The severest of these side effects are nausea and vomiting. We have used metocroplamid for prevening nausea and vomiting. But the prevention of nausea in normal dosage is very difficult. So we have used it at a high dose. In these cases, we have sometimes found side effects. This time we used granisetron instead of metocroplamid, and the following results were obtained.
1. Effective rate of granisetron for nausea and vomiting was 100 % in all cases after 24 hours.
2. Effective rate of granisetron for nausea and vomiting was 100 % in 3 mg/day/body group and 90.9 % in 6 mg/day/body group after 6 days.
3. There was no reduction of the effect of granisetron when we infused cisplatin several times.
4. While using granisetron, however, appetite was decreased. But this duration time was short.
5. No side effect that was thought to be caused by granisetron was found.
Content from these authors
© JAPANESE SOCIETY OF ORAL THERAPEUTICS AND PHARMACOLOGY
Previous article Next article
feedback
Top